Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects

Evogliptin is a newly developed dipeptidyl peptidase-4 (DPP-4) inhibitor, which is expected to be combined with metformin for treating type 2 diabetes mellitus. We investigated the potential pharmacokinetic and pharmacodynamic interactions between evogliptin and metformin. A randomized, open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhee, Su-jin, Choi, YoonJung, Lee, SeungHwan, Oh, Jaeseong, Kim, Sung-Jin, Yoon, Seo Hyun, Cho, Joo-Youn, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986685/
https://www.ncbi.nlm.nih.gov/pubmed/27570447
http://dx.doi.org/10.2147/DDDT.S110712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986685/
https://www.ncbi.nlm.nih.gov/pubmed/27570447
http://dx.doi.org/10.2147/DDDT.S110712

Ejemplares similares